Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study

Soluble urokinase plasminogen activator receptor (suPAR) is an emerging biomarker associated with anatomical CAD burden and cardiovascular outcomes including myocardial infarction (MI) and death. We aimed to validate previous findings of the prognostic value of suPAR and to evaluate its diagnostic p...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers 2022-04, Vol.27 (3), p.278-285
Main Authors: Walter, Joan Elias, Amrein, Melissa Lee Fen, Schäfer, Ibrahim, Zimmermann, Tobias, Lopez-Ayala, Pedro, Boeddinghaus, Jasper, Twerenbold, Raphael, Puelacher, Christian, Nestelberger, Thomas, Wussler, Desiree, Honegger, Ursina, Badertscher, Patrick, Eugen-Olsen, Jesper, Koechlin, Luca, Fahrni, Gregor, Jeger, Raban, Kaiser, Christoph, Zellweger, Michael, Mueller, Christian
Format: Article
Language:English
Subjects:
Biomarkers
CAD
cardiac marker
clinical-utility
Coronary Angiography
Coronary Artery Disease - diagnosis
Humans
Myocardial Infarction - diagnosis
Prognosis
Prospective Studies
Receptors, Urokinase Plasminogen Activator
risk-stratification
SuPAR
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soluble urokinase plasminogen activator receptor (suPAR) is an emerging biomarker associated with anatomical CAD burden and cardiovascular outcomes including myocardial infarction (MI) and death. We aimed to validate previous findings of the prognostic value of suPAR and to evaluate its diagnostic potential for functional relevant CAD (fCAD). Consecutive patients with suspected fCAD were enrolled. Adjudication of fCAD was performed blinded to suPAR concentrations by myocardial perfusion single-photon emission tomography (MPI-SPECT) and coronary angiography. Prognostic outcome measures included all-cause death, cardiovascular death, and incident MI during 2-year follow-up. Among consecutive 968 patients, suPAR concentrations were higher in patients with fCAD compared to those without (3.45 vs. 3.20 ng/mL, p = 0.007), but did not provide acceptable diagnostic accuracy (area under the curve [AUC]: 0.56, 95%CI 0.52-0.60). SuPAR correlated with high-sensitivity cardiac-troponin T (Spearman's rho (ρ) 0.393, p 
ISSN:1354-750X
1366-5804
DOI:10.1080/1354750X.2022.2038269